论文部分内容阅读
目的探讨血管紧张素Ⅱ受体拮抗剂对早期糖尿病肾病(DN)患者血清同型半胱氨酸(Hcy)及C反应蛋白(CRP)的影响。方法 80例早期糖尿病肾病患者,随机分为对照组40例,治疗组40例,对比2组患者糖化血红蛋白(HbA1c)、尿微量蛋白排泄率(UAER)、患者Hcy及CRP水平变化。结果与对照组比较,治疗组降低UAER和HbA1c水平明显优于对照组,两组间比较差异有统计学意义(P<0.05),两组患者治疗前后Hcy和CRP水平比较,治疗组Hcy和CRP水平明显降低,与对照组比较差异有统计学意义(P<0.01)。结论血管紧张素Ⅱ受体拮抗剂能够改善早期DN患者临床疗效,能延缓DN病程的进展,其机理与降低Hcy和CRP水平有一定关系。
Objective To investigate the effects of angiotensin Ⅱ receptor antagonist on serum homocysteine (Hcy) and C-reactive protein (CRP) in patients with early diabetic nephropathy (DN). Methods Eighty patients with early diabetic nephropathy were randomly divided into control group (n = 40) and treatment group (n = 40). HbA1c, urinary protein excretion rate (UAER) and Hcy and CRP levels were compared between the two groups. Results Compared with the control group, the levels of UAER and HbA1c in the treatment group were significantly better than those in the control group, with significant difference between the two groups (P <0.05). The levels of Hcy and CRP in the two groups before and after treatment were significantly higher than those in the control group The level was significantly lower, compared with the control group, the difference was statistically significant (P <0.01). Conclusion Angiotensin Ⅱ receptor antagonist can improve clinical efficacy in patients with early DN and delay the progression of DN. The mechanism is related to the decrease of Hcy and CRP levels.